Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease
Status:
Completed
Trial end date:
2013-07-08
Target enrollment:
Participant gender:
Summary
Cushing's disease is a rare serious condition that is caused by an adrenocorticotropic
hormone (ACTH) secreting pituitary adenoma. This study assessed the long-term safety and
efficacy of pasireotide in participants with Cushing's disease.